Influence of increased body mass index on drug toxicity in patients with acute promyelocytic leukemia.
Thomas
X
X
Fiere
D
D
Archimbaud
E
E
D000328:Adult; D000368:Aged; D000677:Amsacrine / Q000008:administration & dosage; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D015992:Body Mass Index; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006321:Heart / Q000187:drug effects; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D009765:Obesity / Q000150:complications; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000473:pathology; D012074:Remission Induction; D014212:Tretinoin / Q000008:administration & dosage
D000903:Antibiotics, Antineoplastic; D000677:Amsacrine; D003561:Cytarabine; D014212:Tretinoin; D015122:Mercaptopurine; D003630:Daunorubicin